February 3, 2020 10:12 AM EST
News Briefing

Rev­o­lu­tion Med­i­cines shoots for $150 mil­lion IPO; No­var­tis vet heads to Boston Phar­ma

Jason Mast

Editor

→ A week af­ter Black­Di­a­mond Ther­a­peu­tics set the ear­ly bar for 2020 IPOs, Rev­o­lu­tion Med­i­cines has priced

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

No­vo Nordisk claims late-stage MASH vic­to­ry, con­tin­u­ing GLP-1's ex­pan­sion

Bio­gen brings in med­ical chief as CFO plans re­tire­ment; Macro­Gen­ics CEO an­nounces de­par­ture

Es­sa’s shares tank as it looks for op­tions af­ter aban­don­ing prostate can­cer drug

Ex­clu­sive: Blood stem cell ther­a­py mak­er Garu­da gets new CEO, adds $47M

FDA re­moves hold on three CARs­gen CAR-T tri­als; Ono pass­es on itolizum­ab

UCB's an­ti-tau Alzheimer's pro­gram fails Phase 2 pri­ma­ry end­point, but high­lights pos­i­tive sec­on­daries

A service from the Financial Times